1. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease).
- Author
-
Drack AV, Mullins RF, Pfeifer WL, Augustine EF, Stasheff SF, and Hong SD
- Subjects
- Child, DNA Mutational Analysis, Dark Adaptation, Electroretinography, Female, Humans, Membrane Glycoproteins genetics, Molecular Chaperones genetics, Mycophenolic Acid therapeutic use, Neuronal Ceroid-Lipofuscinoses diagnosis, Neuronal Ceroid-Lipofuscinoses genetics, Photic Stimulation, Retinal Degeneration diagnosis, Retinal Degeneration genetics, Retrospective Studies, Tomography, Optical Coherence, Visual Acuity drug effects, Immunosuppressive Agents therapeutic use, Mycophenolic Acid analogs & derivatives, Neuronal Ceroid-Lipofuscinoses drug therapy, Retinal Degeneration drug therapy
- Abstract
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) presents with progressive vision loss at 4-7 years of age. Blindness results within 2 years, followed by inexorable neurologic decline and death. There is no treatment or cure. Neuroinflammation is postulated to play a role in the neurodegeneration. The JNCL mouse model demonstrated decreased neuroinflammation and improved motor skills with immunosuppression. Based on this work, a short-term human clinical trial of mycophenolate mofetil has begun, however longer term effects, and whether immunosuppression modulates vision loss, have not been studied. We report a JNCL patient treated with immunosuppressive therapy in whom visual function was comprehensively characterized over 2 years.
- Published
- 2015
- Full Text
- View/download PDF